- Sort by Relevance
- Display 15 Products per page
Successful Commercialization Strategies for New Healthcare Products and Technologies
Published: June 1, 2003 | Price: $995.00 – $2,992.00
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) more than 1,000 drugs are in various stages of development. Similarly, breakthroughs in the medical device arena such as coronary stents, implantable defibrillators, and minimally invasive bypass surgery and advances in DNA-based tests and other advanced diagnostics are detecting cancer and other diseases earlier when they are more treatable are moving from dream to reality. It is obvious that even if all of these drugs and devices make it to...
Drug-Eluting Stents: Markets and Technologies
Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...
Diabetes in Germany: The Markets for Monitoring, Insulin, Oral Hypoglycemics, and Drugs to Treat Complications
Published: April 1, 2003 | Price: $371.00 – $742.00
The market for diabetes care products covers the spectrum of clinical medicine, including diagnostics, biologics, and drugs. Several areas have strong growth potential and others, such as drugs to treat complications, represent large underserved markets for drugs primarily marketed to other populations. Segmentation of patient populations in novel ways, such as diabetic candidates for cardiovascular drugs, presents an excellent opportunity to expand markets and influence prescription practices in some markets. Scope and Methodology In addition to epidemiology of diabetes Type...
Diabetes in Japan: The Markets for Monitoring, Insulin, Oral Hypoglycemics, and Drugs to Treat Complications
Published: April 1, 2003 | Price: $371.00 – $742.00
The market for diabetes care products covers the spectrum of clinical medicine, including diagnostics, biologics, and drugs. Several areas have strong growth potential and others, such as drugs to treat complications, represent large underserved markets for drugs primarily marketed to other populations. Segmentation of patient populations in novel ways, such as diabetic candidates for cardiovascular drugs, presents an excellent opportunity to expand markets and influence prescription practices in some markets. Scope and Methodology In addition to epidemiology of diabetes Type...
Diabetes in France: The Markets for Monitoring, Insulin, Oral Hypoglycemics, and Drugs to Treat Complications
Published: March 1, 2003 | Price: $371.00 – $742.00
Diabetes monitoring and therapeutics to manage the disease and its complications continues to be an attractive market for many manufacturers. However, the factors that affect the potential of diabetes markets—including population demographics and the attitude of healthcare policy makers and clinicians—can seem like shifting sands from one country to the next. That’s why Kalorama is now offering affordable country-specific profiles on the diabetes markets that provide you with the facts you need to implement your strategy in each of the...